Women administered a non-specific VEGFA/dopamine antagonist cabergoline on the day of hCG trigger also report reduced risk for development of early onset OHSS [33], and cabergoline reduced leakage of a small molecular weight contrast reagent (Gd-DTPA-BMA) out of ovaries when administered starting the day of hCG [34]. This evidence concerns the gene VEGFA and ovarian hyperstimulation syndrome.